News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,362 Results
Type
Article (67031)
Company Profile (306)
Press Release (664025)
Section
Business (204610)
Career Advice (3048)
Deals (36029)
Drug Delivery (106)
Drug Development (85094)
Employer Resources (170)
FDA (16669)
Job Trends (15675)
News (352157)
Policy (34371)
Tag
Academia (2898)
Alliances (51473)
Alzheimer's disease (1395)
Approvals (16610)
Artificial intelligence (184)
Bankruptcy (323)
Best Places to Work (12169)
Biotechnology (203)
Breast cancer (210)
Cancer (1588)
Cardiovascular disease (137)
Career advice (2576)
CAR-T (119)
Cell therapy (344)
Clinical research (67819)
Collaboration (596)
Compensation (291)
COVID-19 (2765)
C-suite (144)
Data (1498)
Diabetes (193)
Diagnostics (6517)
Earnings (77822)
Employer resources (150)
Events (112871)
Executive appointments (500)
FDA (17470)
Funding (534)
Gene therapy (240)
GLP-1 (698)
Government (4901)
Healthcare (19969)
Infectious disease (2870)
Inflammatory bowel disease (129)
Interviews (576)
IPO (16619)
Job creations (3971)
Job search strategy (2160)
Layoffs (485)
Legal (8139)
Lung cancer (239)
Manufacturing (219)
Medical device (13568)
Medtech (13573)
Mergers & acquisitions (19697)
Metabolic disorders (527)
Neuroscience (1787)
NextGen: Class of 2025 (7138)
Non-profit (4952)
Northern California (1854)
Obesity (293)
Opinion (243)
Patents (139)
People (61029)
Phase I (20974)
Phase II (29702)
Phase III (22272)
Pipeline (621)
Postmarket research (3012)
Preclinical (9194)
Radiopharmaceuticals (256)
Rare diseases (317)
Real estate (6416)
Regulatory (23003)
Research institute (2596)
Resumes & cover letters (468)
Southern California (1623)
Startups (3691)
United States (16859)
Vaccines (661)
Weight loss (220)
Date
Last 7 days (682)
Last 30 days (1963)
Last 365 days (35881)
2025 (1648)
2024 (36316)
2023 (40794)
2022 (52013)
2021 (56895)
2020 (55827)
2019 (49372)
2018 (37456)
2017 (34323)
2016 (34343)
2015 (40071)
2014 (33759)
2013 (29883)
2012 (31388)
2011 (31240)
2010 (30150)
Location
Africa (1037)
Arizona (180)
Asia (43000)
Australia (7565)
California (4242)
Canada (1532)
China (374)
Colorado (195)
Connecticut (218)
Europe (98991)
Florida (602)
Georgia (150)
Illinois (455)
Indiana (242)
Maryland (697)
Massachusetts (3310)
Michigan (193)
Minnesota (303)
New Jersey (1222)
New York (1216)
North Carolina (863)
Northern California (1854)
Ohio (157)
Pennsylvania (987)
South America (1368)
Southern California (1623)
Texas (618)
Utah (123)
Washington State (434)
731,362 Results for "national institute of allergy and infectious diseases niaid".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Traverse Biotech Awarded Phase I SBIR Grant by the National Institute of Allergy and Infectious Diseases for Development of Innate Immune Stimulator
Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
May 1, 2024
·
1 min read
Press Releases
Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)
October 1, 2024
·
6 min read
BioCapital
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).
March 28, 2024
·
3 min read
Genetown
BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell
BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell.
March 7, 2024
·
4 min read
Press Releases
ATCC Announces Award from NIAID to Support Preclinical Models of Infectious Diseases
September 27, 2024
·
3 min read
Business
ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Support Its Preclinical Services for Biopharmaceutical Product Development
ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).
November 7, 2023
·
2 min read
Press Releases
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
November 13, 2024
·
3 min read
Drug Development
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has submitted a grant application to the National Institute of Allergy and Infectious Diseases (NIAID) for funding to support Napo’s Phase I study of NP-300.
September 12, 2023
·
5 min read
VyraMed’s Multi-Tissue Platform (MTP) from FetTech Found Highly Effective at Preventing VZV (Shingles) From Spreading in the Skin in NIAID-Sponsored Ex Vivo Human Skin Study
VyraMed and FetTech announced today initial results emerging from their ex vivo human skin study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
December 7, 2023
·
3 min read
Biotech Beach
Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus
Trethera Corporation announced that it was awarded a $0.6M Small Business Technology Transfer grant from the National Institute for Allergy and Infectious Diseases.
June 27, 2023
·
6 min read
1 of 73,137
Next
